vs
帕森斯公司（PSN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
帕森斯公司的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 3.5%，领先9.2%），Revvity同比增速更快（5.9% vs 3.0%），过去两年Revvity的营收复合增速更高（9.0% vs -5.5%）
帕森斯公司是一家总部位于美国弗吉尼亚州尚蒂利的跨国企业，1944年成立，核心业务覆盖国防、情报、基础设施工程领域，深耕技术研发，在全球30多个国家为政府及私营部门客户提供专业解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PSN vs RVTY — 直观对比
营收规模更大
PSN
是对方的1.9倍
$772.1M
营收增速更快
RVTY
高出2.9%
3.0%
净利率更高
RVTY
高出9.2%
3.5%
两年增速更快
RVTY
近两年复合增速
-5.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $52.9M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 6.4% | 14.5% |
| 净利率 | 3.5% | 12.7% |
| 营收同比 | 3.0% | 5.9% |
| 净利润同比 | -20.1% | 3.9% |
| 每股收益（稀释后） | $0.49 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PSNRVTY
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.6B | $772.1M | ||
| Q3 25 | $1.6B | $698.9M | ||
| Q2 25 | $1.6B | $720.3M | ||
| Q1 25 | $1.6B | $664.8M | ||
| Q4 24 | $1.7B | $729.4M | ||
| Q3 24 | $1.8B | $684.0M | ||
| Q2 24 | $1.7B | $691.7M |
净利润PSNRVTY
| Q1 26 | $52.9M | — | ||
| Q4 25 | $55.6M | $98.4M | ||
| Q3 25 | $64.1M | $46.7M | ||
| Q2 25 | $55.2M | $53.9M | ||
| Q1 25 | $66.2M | $42.2M | ||
| Q4 24 | $201.3M | $94.6M | ||
| Q3 24 | $72.0M | $94.4M | ||
| Q2 24 | $69.2M | $55.4M |
毛利率PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 23.0% | — | ||
| Q3 25 | 22.2% | 53.6% | ||
| Q2 25 | 22.0% | 54.5% | ||
| Q1 25 | 22.8% | 56.5% | ||
| Q4 24 | 21.3% | — | ||
| Q3 24 | 19.9% | 56.3% | ||
| Q2 24 | 21.0% | 55.7% |
营业利润率PSNRVTY
| Q1 26 | 6.4% | — | ||
| Q4 25 | 6.6% | 14.5% | ||
| Q3 25 | 6.7% | 11.7% | ||
| Q2 25 | 6.0% | 12.6% | ||
| Q1 25 | 7.0% | 10.9% | ||
| Q4 24 | 5.8% | 16.3% | ||
| Q3 24 | 6.4% | 14.3% | ||
| Q2 24 | 6.7% | 12.4% |
净利率PSNRVTY
| Q1 26 | 3.5% | — | ||
| Q4 25 | 3.5% | 12.7% | ||
| Q3 25 | 4.0% | 6.7% | ||
| Q2 25 | 3.5% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | 11.6% | 13.0% | ||
| Q3 24 | 4.0% | 13.8% | ||
| Q2 24 | 4.1% | 8.0% |
每股收益（稀释后）PSNRVTY
| Q1 26 | $0.49 | — | ||
| Q4 25 | $0.51 | $0.86 | ||
| Q3 25 | $0.59 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $0.60 | $0.35 | ||
| Q4 24 | $1.85 | $0.77 | ||
| Q3 24 | $0.65 | $0.77 | ||
| Q2 24 | $0.63 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $2.8B | $7.3B |
| 总资产 | $6.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.55× | — |
8季度趋势，按日历期对齐
现金及短期投资PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $466.4M | $919.9M | ||
| Q3 25 | $422.6M | $931.4M | ||
| Q2 25 | $411.3M | $991.8M | ||
| Q1 25 | $269.7M | $1.1B | ||
| Q4 24 | $453.5M | $1.2B | ||
| Q3 24 | $558.8M | $1.2B | ||
| Q2 24 | $528.5M | $2.0B |
总债务PSNRVTY
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $785.2M | — | ||
| Q4 24 | $784.1M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — |
股东权益PSNRVTY
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.6B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.5B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.2B | $7.9B |
总资产PSNRVTY
| Q1 26 | $6.0B | — | ||
| Q4 25 | $5.8B | $12.2B | ||
| Q3 25 | $5.7B | $12.1B | ||
| Q2 25 | $5.7B | $12.4B | ||
| Q1 25 | $5.4B | $12.4B | ||
| Q4 24 | $5.5B | $12.4B | ||
| Q3 24 | $5.4B | $12.8B | ||
| Q2 24 | $5.2B | $13.4B |
负债/权益比PSNRVTY
| Q1 26 | 0.55× | — | ||
| Q4 25 | 0.47× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $167.5M | $182.0M | ||
| Q3 25 | $162.8M | $138.5M | ||
| Q2 25 | $159.8M | $134.3M | ||
| Q1 25 | $-11.8M | $128.2M | ||
| Q4 24 | $126.8M | $174.2M | ||
| Q3 24 | $299.0M | $147.9M | ||
| Q2 24 | $161.2M | $158.6M |
自由现金流PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $135.6M | $161.8M | ||
| Q3 25 | $149.7M | $120.0M | ||
| Q2 25 | $150.4M | $115.5M | ||
| Q1 25 | $-25.3M | $112.2M | ||
| Q4 24 | $108.0M | $149.8M | ||
| Q3 24 | $287.3M | $125.6M | ||
| Q2 24 | $152.0M | $136.6M |
自由现金流率PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 8.5% | 21.0% | ||
| Q3 25 | 9.2% | 17.2% | ||
| Q2 25 | 9.5% | 16.0% | ||
| Q1 25 | -1.6% | 16.9% | ||
| Q4 24 | 6.2% | 20.5% | ||
| Q3 24 | 15.9% | 18.4% | ||
| Q2 24 | 9.1% | 19.7% |
资本支出强度PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 1.1% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% |
现金转化率PSNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.01× | 1.85× | ||
| Q3 25 | 2.54× | 2.97× | ||
| Q2 25 | 2.89× | 2.49× | ||
| Q1 25 | -0.18× | 3.03× | ||
| Q4 24 | 0.63× | 1.84× | ||
| Q3 24 | 4.16× | 1.57× | ||
| Q2 24 | 2.33× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PSN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
